BioNxt Solutions Inc. (CSE: BNXT)

Market Cap	23.73M
Revenue (ttm)	30.64K
Net Income (ttm)	-6.42M
Shares Out	113.02M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,100
Open	0.210
Previous Close	0.200
Day's Range	0.210 - 0.210
52-Week Range	0.170 - 0.750
Beta	0.60
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2024

About BioNxt Solutions

BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detectio...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: BNXT

Financial Performance

In 2023, BioNxt Solutions's revenue was 372,247, an increase of 25.15% compared to the previous year's 297,442. Losses were -7.72 million, -37.60% less than in 2022.